Status: Recruiting
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor as per standard clinical practice. Blood and tissue samples will be collected for biomarker analysis, including thymidine kinase1 activity, gene expression signatures and circulating tumor DNA.
Participants needed: 150
Trial details
Biological sex: FemaleType: ObservationalSponsor: Fondazione Sandro PitiglianiUpdated: Feb 26, 2025Locations: 1Duration: 5 Years
Eligibility criteria
Women aged 18 years or older, with a diagnosis of metastatic breast cancer [+6]
Patients with metastatic disease isolated to the central nervous system (CNS) wi... [+1]